Syed Ali Ahsan, Md. Abu Salim, Ayesha Rafiq, Abu Siddique, S.K. Banerjee, Harisul Haque, Manzoor Mahmood
{"title":"孟加拉国一家三级医院经皮冠状动脉介入治疗(PCI)期间单次注射依替巴肽的短期疗效","authors":"Syed Ali Ahsan, Md. Abu Salim, Ayesha Rafiq, Abu Siddique, S.K. Banerjee, Harisul Haque, Manzoor Mahmood","doi":"10.1016/j.cvdpc.2011.04.001","DOIUrl":null,"url":null,"abstract":"<div><h3>Objectives</h3><p>To evaluate the effectiveness of a single bolus dose of eptifibatide in elective percutaneous coronary intervention.</p></div><div><h3>Methods</h3><p>The outcomes of 85 consecutive patients who underwent elective coronary stenting from January 2007 to December 2007 were assessed prospectively. Forty-four patients received eptifibrate (15<!--> <!-->mg single bolus dose) after crossing the lesion and 41 patients did not receive eptifibatide. All patients were treated with aspirin and clopidogrel before and after the procedure and all received a single bolus dose of clopidogrel (300<!--> <!-->mg) before the procedure. All patients received weight-adjusted doses of heparin before and after the procedure. The primary endpoint for the study was the 30-day incidence of death, myocardial infarction, urgent repeat revascularization or in-hospital major bleeding. Major adverse cardiac events were assessed during hospitalization and one month post-procedure. CK-MB was measured post-procedure in all symptomatic patients.</p></div><div><h3>Results</h3><p>Mean age of Group I (Eptifibatide used) was 52.34<!--> <!-->±<!--> <!-->8.90<!--> <!-->years, and Group-II (Eptifibatide not used) was 49.68<!--> <!-->±<!--> <!-->8.87<!--> <!-->years. In group-I 38.63% had history of Myocardial Infarction (MI), 9.09% had history of Unstable angina (UA), 52.27% had history to chronic stable angina (SA), 54.54% was hypertensive, 40.90% were diabetic, 63.63% had dyslipidemia; 56.81% was diagnoses as single vessel disease (SVD), 36.36% was double vessel disease (DVD). Among group-II patients, 36.58 5 had history of MI, 12.19% had history of UA, 51.21% had history of SA, 51.21% was hypertensive, 26.82% was diabetic, 60.97% had dyslipidemia, 63.41% was diagnosed as a SVD, 29.26% was DVD. In short term (one month) outcome, Group I patients had statistically significant less complications in comparison to Group-II patient (<em>p</em> <!-->=<!--> <!-->0.017). In Group-I only 2.27% had Q wave MI AND 2.27% had minor bleeding complication, whereas in Group-II patients 9.76% had Q wave MI, 7.32% had Non-Q MI and 4.88% needed target vessel revascularization again.</p></div><div><h3>Conclusion</h3><p>Single-bolus eptifibatide is a safe and highly cost-effective alternative to conventional regimens.</p></div>","PeriodicalId":11021,"journal":{"name":"Cvd Prevention and Control","volume":"6 3","pages":"Pages 67-70"},"PeriodicalIF":0.0000,"publicationDate":"2011-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1016/j.cvdpc.2011.04.001","citationCount":"0","resultStr":"{\"title\":\"Short-term outcome of single-bolus dose of eptifibatide during percutaneous coronary intervention (PCI) in a tertiary level hospital in Bangladesh\",\"authors\":\"Syed Ali Ahsan, Md. Abu Salim, Ayesha Rafiq, Abu Siddique, S.K. Banerjee, Harisul Haque, Manzoor Mahmood\",\"doi\":\"10.1016/j.cvdpc.2011.04.001\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<div><h3>Objectives</h3><p>To evaluate the effectiveness of a single bolus dose of eptifibatide in elective percutaneous coronary intervention.</p></div><div><h3>Methods</h3><p>The outcomes of 85 consecutive patients who underwent elective coronary stenting from January 2007 to December 2007 were assessed prospectively. Forty-four patients received eptifibrate (15<!--> <!-->mg single bolus dose) after crossing the lesion and 41 patients did not receive eptifibatide. All patients were treated with aspirin and clopidogrel before and after the procedure and all received a single bolus dose of clopidogrel (300<!--> <!-->mg) before the procedure. All patients received weight-adjusted doses of heparin before and after the procedure. The primary endpoint for the study was the 30-day incidence of death, myocardial infarction, urgent repeat revascularization or in-hospital major bleeding. Major adverse cardiac events were assessed during hospitalization and one month post-procedure. CK-MB was measured post-procedure in all symptomatic patients.</p></div><div><h3>Results</h3><p>Mean age of Group I (Eptifibatide used) was 52.34<!--> <!-->±<!--> <!-->8.90<!--> <!-->years, and Group-II (Eptifibatide not used) was 49.68<!--> <!-->±<!--> <!-->8.87<!--> <!-->years. In group-I 38.63% had history of Myocardial Infarction (MI), 9.09% had history of Unstable angina (UA), 52.27% had history to chronic stable angina (SA), 54.54% was hypertensive, 40.90% were diabetic, 63.63% had dyslipidemia; 56.81% was diagnoses as single vessel disease (SVD), 36.36% was double vessel disease (DVD). Among group-II patients, 36.58 5 had history of MI, 12.19% had history of UA, 51.21% had history of SA, 51.21% was hypertensive, 26.82% was diabetic, 60.97% had dyslipidemia, 63.41% was diagnosed as a SVD, 29.26% was DVD. In short term (one month) outcome, Group I patients had statistically significant less complications in comparison to Group-II patient (<em>p</em> <!-->=<!--> <!-->0.017). In Group-I only 2.27% had Q wave MI AND 2.27% had minor bleeding complication, whereas in Group-II patients 9.76% had Q wave MI, 7.32% had Non-Q MI and 4.88% needed target vessel revascularization again.</p></div><div><h3>Conclusion</h3><p>Single-bolus eptifibatide is a safe and highly cost-effective alternative to conventional regimens.</p></div>\",\"PeriodicalId\":11021,\"journal\":{\"name\":\"Cvd Prevention and Control\",\"volume\":\"6 3\",\"pages\":\"Pages 67-70\"},\"PeriodicalIF\":0.0000,\"publicationDate\":\"2011-09-01\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"https://sci-hub-pdf.com/10.1016/j.cvdpc.2011.04.001\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Cvd Prevention and Control\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://www.sciencedirect.com/science/article/pii/S1875457011000489\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"\",\"JCRName\":\"\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Cvd Prevention and Control","FirstCategoryId":"1085","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S1875457011000489","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 0
摘要
目的评价单次大剂量依替巴肽在择期经皮冠状动脉介入治疗中的疗效。方法对2007年1月至2007年12月连续行择期冠状动脉支架植入术的85例患者的预后进行前瞻性评价。44例患者在穿过病变后接受依替巴肽(15 mg单次剂量)治疗，41例患者未接受依替巴肽治疗。所有患者在手术前后均接受阿司匹林和氯吡格雷治疗，所有患者在手术前均接受单次剂量氯吡格雷(300毫克)治疗。所有患者在手术前后均接受体重调整剂量的肝素治疗。研究的主要终点是30天内死亡、心肌梗死、紧急重复血运重建术或院内大出血的发生率。主要心脏不良事件在住院期间和术后1个月进行评估。所有有症状的患者术后均测量CK-MB。结果ⅰ组(使用依替巴肽)平均年龄为52.34±8.90岁，ⅱ组(未使用依替巴肽)平均年龄为49.68±8.87岁。ⅰ组38.63%有心肌梗死(MI)史，9.09%有不稳定型心绞痛(UA)史，52.27%有慢性稳定型心绞痛(SA)史，54.54%有高血压，40.90%有糖尿病，63.63%有血脂异常;单支血管病变(SVD)占56.81%，双支血管病变(DVD)占36.36%。ii组患者有心肌梗死史36.585例，UA史12.19%，SA史51.21%，高血压51.21%，糖尿病26.82%，血脂异常60.97%，SVD 63.41%， DVD 29.26%。在短期(1个月)结果中，I组患者的并发症较ii组患者有统计学意义(p = 0.017)。组中Q波心肌梗死发生率为2.27%，轻度出血并发症发生率为2.27%，组中Q波心肌梗死发生率为9.76%，非Q波心肌梗死发生率为7.32%，需再次行靶血管重建术的发生率为4.88%。结论单次注射依替巴肽是一种安全、经济的替代方案。
Short-term outcome of single-bolus dose of eptifibatide during percutaneous coronary intervention (PCI) in a tertiary level hospital in Bangladesh
Objectives
To evaluate the effectiveness of a single bolus dose of eptifibatide in elective percutaneous coronary intervention.
Methods
The outcomes of 85 consecutive patients who underwent elective coronary stenting from January 2007 to December 2007 were assessed prospectively. Forty-four patients received eptifibrate (15 mg single bolus dose) after crossing the lesion and 41 patients did not receive eptifibatide. All patients were treated with aspirin and clopidogrel before and after the procedure and all received a single bolus dose of clopidogrel (300 mg) before the procedure. All patients received weight-adjusted doses of heparin before and after the procedure. The primary endpoint for the study was the 30-day incidence of death, myocardial infarction, urgent repeat revascularization or in-hospital major bleeding. Major adverse cardiac events were assessed during hospitalization and one month post-procedure. CK-MB was measured post-procedure in all symptomatic patients.
Results
Mean age of Group I (Eptifibatide used) was 52.34 ± 8.90 years, and Group-II (Eptifibatide not used) was 49.68 ± 8.87 years. In group-I 38.63% had history of Myocardial Infarction (MI), 9.09% had history of Unstable angina (UA), 52.27% had history to chronic stable angina (SA), 54.54% was hypertensive, 40.90% were diabetic, 63.63% had dyslipidemia; 56.81% was diagnoses as single vessel disease (SVD), 36.36% was double vessel disease (DVD). Among group-II patients, 36.58 5 had history of MI, 12.19% had history of UA, 51.21% had history of SA, 51.21% was hypertensive, 26.82% was diabetic, 60.97% had dyslipidemia, 63.41% was diagnosed as a SVD, 29.26% was DVD. In short term (one month) outcome, Group I patients had statistically significant less complications in comparison to Group-II patient (p = 0.017). In Group-I only 2.27% had Q wave MI AND 2.27% had minor bleeding complication, whereas in Group-II patients 9.76% had Q wave MI, 7.32% had Non-Q MI and 4.88% needed target vessel revascularization again.
Conclusion
Single-bolus eptifibatide is a safe and highly cost-effective alternative to conventional regimens.
京公网安备 11010802042870号
京ICP备2023020795号-1
分享
求助内容：
应助结果提醒方式：
扫码关注我们
